JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 77 filers reported holding JOUNCE THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $176,490 | -54.0% | 159,000 | -3.0% | 0.01% | -50.0% |
| Q3 2022 | $384,000 | +77.8% | 164,000 | +424.0% | 0.01% | +150.0% |
| Q2 2020 | $216,000 | -86.0% | 31,300 | -90.4% | 0.00% | -88.6% |
| Q1 2020 | $1,546,000 | -21.6% | 325,500 | +44.1% | 0.04% | +29.6% |
| Q4 2019 | $1,972,000 | +285.9% | 225,900 | +47.1% | 0.03% | +285.7% |
| Q3 2019 | $511,000 | -58.4% | 153,600 | -38.0% | 0.01% | -56.2% |
| Q2 2019 | $1,227,000 | -12.9% | 247,900 | +9.2% | 0.02% | -11.1% |
| Q1 2019 | $1,408,000 | +40.1% | 227,100 | -23.9% | 0.02% | +38.5% |
| Q4 2018 | $1,005,000 | -23.9% | 298,300 | +46.7% | 0.01% | 0.0% |
| Q3 2018 | $1,321,000 | – | 203,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
| TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
| Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
| Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
| Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
| PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
| Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
| Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
| ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |